Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Accepted: 25 July 2025
First Online: 15 August 2025
Competing interests
: During the past 48 months, S.G.W. has served as an adviser to SiteOne Therapeutics, Navega Therapeutics, Channel Therapeutics, OliPass Biotherapeutics, Latigo Therapeutics, Sangamo, Third Rock Ventures, Foresite Labs, Exicure, Arrowhead Pharmaceuticals, GenEP, Enveda Bioscience, Spark Therapeutics, Jazz Therapeutics, Alnylam, Population Health Partners, Medtronics and Vertex.
